FDA-Cleared Indication
Aeromonas infection prevention is a well-established clinical safety practice for medicinal leech therapy. While the FDA 510(k) clearance for K040187 does not itself specify a prophylaxis regimen, antibiotic prophylaxis against Aeromonas is recommended in the published literature (Lineaweaver 1992; Mumcuoglu 2014; Herlin 2017).
Without prophylaxis, infection follows 2.4–20% of leech-treated microsurgical cases. With antibiotic prophylaxis, the reported rate of inflammatory complications is much lower (about 4.7% in one literature review), although breakthrough infections with resistant strains still occur — prophylaxis is a core safety intervention in the protocol.Whitaker IS et al. 2012 (Microsurgery); Mackay DR et al. 1999 (Ann Plast Surg)
GRADE Evidence Level: Moderate
RCTs with limitations or strong observational studies
Aeromonas (mainly A. veronii, long reported as A. hydrophila) is the single most important infectious risk of medicinal leech therapy, accounting for an estimated 88% of all leech-associated infectious complications. These gram-negative bacteria are not contaminants but long-recognized symbionts of the medicinal leech digestive tract: A. veronii is the main culturable bacterium in the crop, and its hemolysin-mediated lysis of erythrocytes is required for colonization of the leech gut. Because Aeromonas is regularly recovered from medicinal leeches, infection prevention is not a possibility to consider but something to plan for.
In most published series the infection rate is 7–20% (de Chalain, 1996). Antibiotic prophylaxis is recommended but does not eliminate the risk: in one cohort, surgical-site infection occurred in 7 patients (11.9%), all of whom had received antimicrobial prophylaxis (Kruer 2015). The clinical stakes are extreme: in the landmark Whitaker et al. (2012) systematic review of 277 cases, overall tissue salvage was ~78%, but fell to 37.4% in infected cases versus 88.3% in uninfected cases, highlighting why prophylaxis is essential.
Microbiology and Pathogenesis
Three Aeromonas species are clinically relevant in hirudotherapy. Understanding their biology is essential for rational prophylaxis design and infection management.
Aeromonas veronii biovar sobria
The predominant gut symbiont of Hirudo verbana (the species most widely used in clinical practice). Identified by Graf (1999) in leeches then sold as Hirudo medicinalis (now recognized as largely H. verbana; Siddall et al. 2007) through biochemical and genetic analysis of intestinal canal extracts from leeches obtained from established suppliers across Europe.
Aeromonas hydrophila
Historically considered the primary pathogen and the species most frequently cited in clinical infection reports. Aeromonas species together account for an estimated 88% of leech-associated infections (Hackenberger & Janis 2019, review). Aeromonas spp. (A. veronii predominant) are recovered from roughly 62% of tested leech batches in one hospital series and from all control leeches in another study.
Aeromonas sobria
Isolated from leech cultures alongside A. hydrophila (Eroglu et al., 2001: A. sobria n = 2 of 73 isolates; Nonomura et al., 1996: Aeromonas spp. in all leeches). Less frequently implicated in clinical infections but contributes to the overall bacterial burden.
Bacterial Growth Kinetics in the Leech Gut
Bacterial density within the leech intestinal canal follows a characteristic growth curve (Graf, 1999): from an initial inoculum of approximately 2 × 104 CFU/mL, the population doubles every 1.2 hours, reaching a plateau of approximately 5 × 107 CFU/mL after 12 hours (total bacteria about 108 CFU/mL) at 23 °C. Graf notes that proteinase inhibitors (bdellin and eglin) have been proposed to restrict further growth, but their role was not demonstrated. This exponential growth means that every leech application introduces a substantial bacterial inoculum into the patient wound.
Virulence Mechanisms
Aeromonas species possess several features that enhance their pathogenicity at the leech bite wound:
- Complement resistance: In Aeromonas strains of serogroup O:11, the S-layer protein (52 kDa) appears to cover the lipopolysaccharide so that complement is not activated and the membrane attack complex (C5b-9) is not formed, rendering the serum bactericidal reaction ineffective (Merino et al., 1996). This partly explains their persistence and virulence at the bite site.
- Enzymatic arsenal: Production of amylase, lipases, and proteases that mediate digestive processes within the leech but can also damage host tissues when introduced into the wound.
- Bacteriostatic protein: A protein that prevents blood coagulation in the leech digestive tract (Khomyakova et al., 2003).
- Chromosomal beta-lactamases: Intrinsic high-level resistance to first-generation cephalosporins and ampicillin/amoxicillin (Hermansdorfer et al., 1988; Janda & Abbott, 2010), limiting empiric antibiotic options.
Infection Rates and Risk Factors
The risk of clinically significant Aeromonas infection following leech therapy is well characterized across multiple published series. The data are unambiguous: prophylaxis is the single most important modifiable factor in determining infection rates and, by extension, surgical outcomes.
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Whitaker et al. 2012 | Systematic review | Plastic and reconstructive surgery patients across 67 publications (1966-2009) (n=277) | Leech therapy with variable prophylaxis (79% received antibiotics) | Infection rate and impact on tissue salvage | ~78% salvage / 277 cases (PMID 22407551) Landmark systematic review. 49.75% transfusion rate. 21.8% overall complication rate |
| de Chalain 1996 | Case series + literature review | 18 own cases plus 108 from published literature (n=126) | Medicinal leech therapy for compromised pedicled flaps and microvascular free-tissue transfers | Aggregate infection rate range | Infection rate of most series 7-20%; flap salvage drops to 30% or less when a clinically significant infection occurs Foundational range estimate still cited in current guidelines |
| Lineaweaver et al. 1992 | Multicenter case series | Replantation and flap surgery patients with A. hydrophila infection (n=10) | Documentation of Aeromonas infections following leech therapy across multiple centers | Infection characteristics, onset timing, and severity spectrum | Onset from 24 hours to 10 days or more; severity from minor wound complications to tissue loss and sepsis Seminal study that established the mandate for routine antibiotic prophylaxis during leech therapy |
| Nguyen et al. 2012 | Retrospective case series | 39 patients treated with leeches for venous congestion in native skin, local, regional and free flaps (n=39) | Leech therapy; no prophylaxis protocol was designed or compared | Aeromonas hydrophila infection rate | No Aeromonas wound infection observed (0/39) Incidental observation in a flap-outcome study; not evidence that a prophylaxis protocol eliminates infection |
| Palm et al. 2022 | Quality improvement study | Patients receiving leech therapy at a tertiary academic medical center (n=40) | Standardized EMR order panel linking leech orders to automatic antibiotic prophylaxis | Infection rate with vs without optimized prophylaxis | Infections occurred exclusively in subset without optimized prophylaxis; zero infections with EMR-linked protocol Systems-level intervention. Panel includes leech order + antibiotics + lab monitoring + nursing protocol |
| Herlin et al. 2017 | Systematic review + retrospective cohort | Free flap patients with venous congestion (41 studies + 43 own cases) (n=43) | Medicinal leeches with ciprofloxacin + TMP-SMX dual prophylaxis | Flap salvage rate and infection profile | 83.7% salvage; ciprofloxacin plus trimethoprim-sulfamethoxazole proposed as the most relevant prophylaxis Established ciprofloxacin + TMP-SMX as the recommended first-line prophylactic combination |
| Rajaram et al. 2024 | Systematic review | Breast reconstruction patients (18 studies) (n=28) | Leech therapy for flap congestion in breast surgery | Complication rate including infection | 75% salvage; 81.1% overall complication rate with infection as a dominant component First systematic review dedicated to breast surgery. Highlights infection burden in this population |
| Schnabl et al. 2010 | Case series | Patients who developed major Aeromonas infections during leech therapy (n=5) | Leech therapy complicated by A. hydrophila infection | Reconstruction success after established infection | Reconstruction unsuccessful in all 5 patients (100% failure rate) Highlights the devastating impact of Aeromonas infection on surgical outcomes |
Key Infection Rate Data
Patient Risk Factors for Aeromonas Infection
High-Risk Conditions
- Immunocompromised state: HIV/AIDS (low CD4 count), organ transplant recipients on immunosuppressants, active chemotherapy, chronic corticosteroid use. At least one case of Aeromonas septicemia in an immunocompromised patient has been documented.
- Diabetes mellitus: Impaired neutrophil function, microvascular disease, and elevated wound infection rates create a compounding risk.
- Peripheral vascular disease: Poor tissue perfusion limits antibiotic delivery to the bite site and impairs local immune response.
- Hematological malignancies: Combined immunosuppression and coagulopathy elevate both infection and bleeding risk.
- Decompensated hepatobiliary disease: Impaired synthesis of complement and clotting factors, portal hypertension with splenic sequestration of immune cells.
Additional Risk Factors
- Absent or inadequate prophylaxis: Associated with significantly higher infection rates (Whitaker et al., 2011). Infections in the Palm et al. (2022) study occurred exclusively in patients without optimized prophylaxis.
- Prolonged leech therapy: Multi-day, multi-session treatment courses increase cumulative bacterial exposure and wound area.
- Prior antibiotic exposure: May select for resistant organisms in the patient's flora, complicating empiric therapy if infection develops.
- Prosthetic material at treatment site: Implanted hardware provides a surface for bacterial adherence and biofilm formation.
- Age extremes: Children under 6 years (higher relative blood loss, dosing challenges) and elderly patients (impaired immune function, comorbidities).
Clinical Presentation and Timeline
Aeromonas wound infection following leech therapy presents along a predictable trajectory. Clinicians should maintain a high index of suspicion for at least 4 weeks following the last leech application. Delayed infections have been reported up to 26 days after the beginning of leech therapy (Mumcuoglu, 2014).
Early Phase (24–72 hours)
- Expanding erythema surrounding the bite site, disproportionate to expected post-procedural inflammation
- Increased warmth, tenderness, and induration at wound margins
- Seropurulent or frankly purulent discharge from the bite wound
- Onset may be as early as 24 hours (Lineaweaver et al., 1992)
Progressive Phase (3–10 days)
- Cellulitis extending beyond the immediate treatment area
- Wound dehiscence in surgical patients
- Flap or graft compromise: color change, turgor loss, decreased capillary refill
- Regional lymphadenitis (slight swelling and pain of regional lymph nodes, subfebrile temperature) in 6.4–13.4% of treated patients, usually after 3-4 leech applications
- Fever, leukocytosis, and elevated inflammatory markers
Late & Severe Manifestations
- Infections documented up to 26 days after the beginning of leech therapy
- Deep tissue abscess requiring surgical drainage
- Partial or complete tissue necrosis necessitating debridement or resection
- Septicemia, including at least one documented lethal case of A. veronii sepsis (Antibiotics, 2022)
- Aeromonas meningitis (Clin Infect Dis, 2004) — rare but documented
Clinical Alert
Antibiotic Prophylaxis Protocols
Antibiotic prophylaxis against Aeromonas species is strongly recommended for all patients receiving leech therapy (Herlin et al., 2017; Mumcuoglu et al., 2014).
Standard Dual-Agent Prophylaxis Protocol
First-line combination (Herlin et al., 2017):
Ciprofloxacin 500 mg PO BID plus Trimethoprim-sulfamethoxazole DS (160/800 mg) PO BID.
Duration: Continue throughout the entire course of leech therapy plus a minimum of 24 hours after the last leech application. Many centers extend prophylaxis to 10–14 days, particularly in immunocompromised patients or those with prosthetic material.
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Ciprofloxacin monotherapy 2017 | Historical standard | General leech therapy patients (n=NR) | Ciprofloxacin 500 mg PO BID | Aeromonas prophylaxis | Historically effective; ciprofloxacin-resistant Aeromonas documented in case reports and in leech-tank surveillance No longer recommended as sole prophylaxis due to rising fluoroquinolone resistance, including plasmid-mediated qnrS2 (77% of isolates from the FDA-approved leech supply chain ciprofloxacin-resistant) |
| Herlin et al. 2017 | Systematic review recommendation | Free flap patients (n=43) | Ciprofloxacin 500 mg + TMP-SMX 160/800 mg PO BID each | Dual-agent prophylaxis | Recommended as the most relevant prophylactic antibiotherapy; low infection rate in own series Current recommended first-line combination |
| Ceftriaxone (institutional protocols) 2022 | Institutional protocol | Inpatient/surgical leech therapy patients (n=NR) | Ceftriaxone 1-2 g IV daily | Third-generation cephalosporin alternative | Excellent Aeromonas coverage; preferred in inpatient/surgical settings Third-generation cephalosporins retain activity unlike first-generation agents |
| TMP-SMX monotherapy 2020 | Alternative regimen | Patients with fluoroquinolone contraindications (n=NR) | TMP-SMX DS 160/800 mg PO BID | Single-agent alternative prophylaxis | Excellent Aeromonas coverage; not subject to the same resistance trends as ciprofloxacin Suitable alternative when fluoroquinolones are contraindicated or batch surveillance shows resistance |
Why Dual-Agent Therapy?
Ciprofloxacin-resistant Aeromonas has been documented after leech therapy, and in one hospital's leech-tank surveillance 6 of 21 isolates were not ciprofloxacin-susceptible while all were TMP-SMX-susceptible (Wilmer et al. 2013). Plasmid-mediated quinolone resistance (PMQR) genes are present in 42.0% (29/69) of Aeromonas isolates from a natural freshwater reservoir — including in strains that remain phenotypically susceptible by standard testing, meaning resistance may be cryptic and emerge under antibiotic pressure (Frontiers in Cellular and Infection Microbiology, 2022). Dual therapy with TMP-SMX provides essential coverage against fluoroquinolone-resistant strains.
Agents to Avoid — Intrinsic Resistance
- First-generation cephalosporins (cefazolin, cephalexin): Intrinsic high-level Aeromonas resistance via chromosomal beta-lactamases (Hermansdorfer et al., 1988; Janda & Abbott, 2010). Never use as sole prophylaxis.
- Ampicillin/amoxicillin: Generally resistant. These agents provide no reliable Aeromonas coverage.
- Clindamycin: No Aeromonas activity. A common empiric choice for soft tissue infections that is ineffective in this context.
Alternative Regimens by Clinical Setting
| Setting | Regimen | Notes |
|---|---|---|
| Outpatient / oral | Ciprofloxacin 500 mg + TMP-SMX DS PO BID | First-line combination per Herlin et al. (2017) |
| Inpatient / surgical | Ceftriaxone 1–2 g IV daily | Third-generation cephalosporin; preferred for IV administration |
| Fluoroquinolone allergy | TMP-SMX DS PO BID as monotherapy | Excellent Aeromonas coverage; not affected by quinolone resistance trends |
| Sulfa allergy | Ciprofloxacin 500 mg PO BID (with batch surveillance) | Monotherapy acceptable only if batch culture confirms susceptibility |
| Immunocompromised | Dual oral + consider ceftriaxone IV overlap | Extended duration (5+ days post-treatment); enhanced monitoring |
| Batch resistance detected | Directed by batch-specific susceptibility profile | Quarantine resistant batches; adjust regimen before clinical use |
EMR-Integrated Order Panels
Poor adherence to prophylaxis protocols has been documented even at major academic medical centers. Palm et al. (2022) evaluated 40 patients receiving leech therapy at a tertiary care center and identified significant gaps in antimicrobial prophylaxis compliance. Their solution — implementation of a standardized electronic medical record (EMR) order panel that automatically links leech therapy orders to antibiotic prophylaxis — resulted in significant improvement in adherence. Infections occurred only in the subset of patients who did not receive optimized prophylaxis. This systems-based approach is strongly recommended for any institution performing leech therapy with regularity.
Recommended EMR Order Panel Components (adapted from Palm et al., 2022)
- Leech therapy order: Species, quantity, frequency, duration
- Linked antibiotic prophylaxis: SMX-TMP recommended first line, ciprofloxacin for sulfa-allergic patients (part of the leech order panel)
- Linked laboratory monitoring: CBC every 8 hours, type and crossmatch
- Linked nursing protocol: Flap assessment frequency, wound care instructions, infection surveillance
- Automatic pharmacy notification: For leech procurement and antibiotic dispensing
The Ciprofloxacin Resistance Crisis
The reliance on ciprofloxacin as first-line monoprophylaxis is increasingly challenged by rising fluoroquinolone resistance among Aeromonas species. This is not a theoretical concern — it is a documented clinical reality with five published cases of prophylaxis failure and alarming environmental resistance data.
Environmental Resistance Data
- 6 of 21 leech-tank Aeromonas isolates not ciprofloxacin-susceptible in one hospital's surveillance (Wilmer 2013)
- 42.0% (29/69) of fluoroquinolone-susceptible Aeromonas isolates from a single Polish recreational freshwater reservoir carried plasmid-mediated quinolone resistance (PMQR) genes
- PMQR genes present even in strains that appear phenotypically susceptible by standard testing — resistance may be cryptic and emerge under antibiotic pressure
- Standard ciprofloxacin prophylaxis may fail where resistant organisms are present
Clinical Implications
- Five published cases over twelve years represent only the reported cases — true incidence of prophylaxis failure is likely underestimated
- Ciprofloxacin monotherapy can no longer be considered reliably protective
- ESBL-producing Aeromonas strains have been identified, further narrowing treatment options
- Proactive batch surveillance is the only strategy that addresses the resistance problem at its source
Published Cases of Ciprofloxacin-Resistant Aeromonas After Leech Therapy (2013–2025)
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Giltner et al. 2013 | Case report | Patient receiving ciprofloxacin prophylaxis during leech therapy (n=1) | Standard ciprofloxacin prophylaxis | Ciprofloxacin-resistant A. hydrophila cellulitis | Cellulitis developed despite appropriate ciprofloxacin prophylaxis; culture confirmed resistance Published in Journal of Clinical Microbiology |
| Patel et al. 2013 | Case report + literature review | Post-leech therapy patient with resistant infection (n=1) | Ciprofloxacin prophylaxis with subsequent resistance | Treatment failure requiring alternative antibiotics | Ciprofloxacin-resistant Aeromonas infection; thorough literature review included Published in Journal of Plastic, Reconstructive & Aesthetic Surgery (JPRAS) |
| Wilmer et al. 2014 | Case series | Digit replantation patients receiving ciprofloxacin prophylaxis (n=2) | Standard ciprofloxacin prophylaxis during digit replantation | Ciprofloxacin-resistant Aeromonas infection in both patients | Two cases of resistant infection following digit replantation despite prophylaxis Published in Journal of Hand Surgery (American Volume) |
| Multidrug-resistant case 2020 | Case report + protocol development | Patient with MDR Aeromonas following leech therapy (n=1) | Leech therapy complicated by multidrug-resistant Aeromonas | Led to development of institutional batch surveillance and antimicrobial stewardship protocol | MDR Aeromonas identified; institutional response protocol developed and implemented with zero subsequent infections Published in IDCases. Catalyzed proactive surveillance approach |
| Ciprofloxacin-resistant case 2025 | Case report | Free flap surgery patient with resistant A. hydrophila (n=1) | Leech therapy for free flap venous congestion | Ciprofloxacin-resistant A. hydrophila complicating surgical outcome | Resistant infection requiring alternative antibiotic therapy; highlights ongoing resistance trend Published in JPRAS Open. Most recent published resistance case |
Institutional Response Strategies
Proactive Batch Surveillance Protocol
The innovative approach of proactive batch-level surveillance was developed following the multidrug-resistant case reported by Masters et al. in J Glob Antimicrob Resist (2020). Rather than waiting for clinical infections to reveal resistance, this protocol identifies resistant organisms before leeches are applied to patients. Implementation of this protocol was followed by no further reported leech-associated infections at the reporting institution.
Surveillance Workflow
- On delivery: Sacrifice one leech per batch of 50 for culture and standard antimicrobial susceptibility testing. Request specific Aeromonas identification and extended-spectrum beta-lactamase (ESBL) testing.
- During storage: Repeat culture of one leech from each stored batch every 30 days to detect any resistance acquisition during storage.
- Prophylaxis adjustment: Direct antibiotic prophylaxis toward the susceptibility profile of the specific batch in clinical use. If the batch is susceptible to ciprofloxacin, standard prophylaxis may proceed; if resistant, adjust to TMP-SMX or cephalosporin-based regimen.
- Quarantine: Batches harboring multidrug-resistant isolates are quarantined and not used for patient care. Notify infection control and antimicrobial stewardship.
- Documentation: Maintain a log of batch culture results, susceptibility profiles, and any quarantine decisions. Link to patient records for traceability.
Results and Evidence
- Masters et al., J Glob Antimicrob Resist (2020): Following implementation of batch surveillance and directed prophylaxis, the institution reported zero subsequent leech-associated infections.
- Palm et al. (2022): A single-center EMR order panel for antimicrobial prophylaxis with medicinal leech orders significantly increased antibiotic ordering and appropriate timing of initiation in the 10 patients treated after implementation; infections were rare before and after implementation and developed only in patients with non-optimized prophylaxis.
- Cost-effectiveness: The cost of sacrificing one leech per 50 ($0.20–$0.30 per leech in the batch) plus microbiology processing is negligible compared with the cost of treating an established Aeromonas infection (prolonged hospitalization, IV antibiotics, potential tissue loss, reoperation).
- Recommendation: All institutions performing leech therapy should implement batch-level surveillance as part of their standard operating procedure.
Treatment of Established Aeromonas Infection
When infection develops despite prophylaxis, or when prophylaxis was not administered, prompt and aggressive management is essential. The Whitaker et al. (2012) data demonstrate that outcomes with established infection are poor: salvage rates drop to 37.4% compared with 88.3% in uninfected patients. Time to appropriate therapy is critical.
Decision Algorithm
Aeromonas suspicion → action algorithm
Apply when a patient on active medicinal-leech therapy develops symptoms suggesting infection.
Is the patient currently receiving medicinal leech therapy?
Symptoms suggesting Aeromonas infection? (fever, erythema spread, purulent drainage, cellulitis)
Severe (sepsis, rapidly spreading cellulitis, systemic compromise)?
Admit + IV ciprofloxacin or 3rd-gen cephalosporin + surgical consult
Aggressive empirical therapy; targeted by culture + sensitivity once available.
Oral ciprofloxacin 500 mg BID × 7–14 days OR TMP-SMX DS BID × 7–14 days
Always obtain wound culture + sensitivity (Aeromonas is intrinsically penicillin-resistant).
Continue prophylaxis throughout leech therapy
Ciprofloxacin 500 mg PO BID OR TMP-SMX DS BID for the full duration of leech therapy + 24 hours after final application.
Mild Infection (Localized)
Criteria: Localized erythema, no systemic signs, no flap compromise
- Obtain wound culture (aerobic; request Aeromonas ID)
- Oral ciprofloxacin 500 mg BID if not already receiving
- Add or switch to TMP-SMX DS BID if on ciprofloxacin monotherapy
- Enhanced wound monitoring (every 4 hours minimum)
- Re-evaluate in 24 hours; escalate if no improvement
Moderate Infection (Regional)
Criteria: Expanding cellulitis, lymphangitis, flap compromise, or fever
- Blood cultures plus wound culture — STAT
- Third-generation cephalosporin IV (ceftriaxone 1–2 g daily or ceftazidime 1–2 g IV q8h)
- Consider adding aminoglycoside (gentamicin) or fluoroquinolone for dual coverage
- Infectious disease consultation
- Assess flap or graft viability — surgical re-exploration if indicated
Severe Infection (Systemic / Necrotizing)
Criteria: Septicemia, necrotizing infection, abscess, hemodynamic instability
- Carbapenems IV (imipenem or meropenem) for multidrug-resistant coverage
- Emergent surgical debridement and drainage
- Assessment of tissue viability — partial or complete resection may be necessary
- ICU monitoring for sepsis management
- Serial wound cultures to confirm bacterial clearance
- Duration: typically 7–14 days for most bacterial soft-tissue infections, continued until further debridement is no longer necessary, the patient has improved clinically, and fever has been absent for 48–72 hours; longer for deep space infections, osteomyelitis, or septicemia
Avoid Monotherapy for Established Infection
Outcomes with Established Infection
| Outcome Measure | Without Infection | With Infection | Source |
|---|---|---|---|
| Tissue salvage rate | 88.3% | 37.4% | Whitaker et al., 2012 |
| Salvage rate decline | 51 percentage-point reduction | Whitaker et al., 2012 | |
| Major infection outcome | N/A | 0/5 reconstruction success | Schnabl et al., 2010 |
Wound Care and Post-Treatment Monitoring
The medicinal leech bite creates a characteristic triradiate (Y-shaped) wound approximately 1 mm in diameter. Each bite site continues to ooze blood for 4 to 24 hours after leech detachment attributed to anticoagulant and antiplatelet components of leech saliva (hirudin, calin), although the mechanism is not fully established. This prolonged oozing is expected and therapeutic (it is the passive decompression mechanism) but creates an open portal for bacterial entry that requires vigilant wound care.
Active Treatment Phase
- Wound site monitoring: Assess at each nursing assessment for erythema, induration, discharge, warmth, and wound margin changes
- Dressing management: Apply saline-moistened gauze to bite sites; permit continued oozing (do not attempt to stop passive bleeding as it provides venous decompression)
- Flap assessment: Document tissue color, turgor, and capillary refill at each assessment
- Hematocrit monitoring: Serial hemoglobin or hematocrit checks every 4 hours during active leech therapy, with the frequency adjusted to the number of leeches used, the frequency of sessions and the total duration of therapy (Mumcuoglu et al., 2014)
- Clinical photographs: Obtain baseline and serial photographs for documentation and comparison
Post-Treatment Phase
- Antibiotic continuation: Maintain prophylaxis for minimum 24 hours after last leech application (Extended courses up to 10–14 days may be considered in immunocompromised patients or when wound healing is delayed)
- Wound surveillance: Monitor for signs of infection for up to 4 weeks post-treatment (late-onset infections documented up to 26 days)
- Bite site healing: Wounds usually heal without scarring, although scarring can occur on thin skin in esthetically important areas
- Scar management: Mature scar is typically flat and hypopigmented, 2–5 mm in diameter; standard scar management strategies (silicone sheeting, sun protection) may be employed
- Follow-up: Scheduled follow-up appointment with wound assessment and culture if any concerning signs
Bleeding Management
Each leech ingests about 5–15 mL of blood during a feeding session, and the bite wound may continue to ooze for up to 24 hours after detachment. In multi-leech, multi-session treatment courses, cumulative blood loss is substantial: the Whitaker et al. (2012) systematic review found that 49.75% of patients required blood transfusions.
When to Intervene for Excessive Bleeding
- Persistent active bleeding beyond 24 hours from a single bite site
- Hemodynamic instability: tachycardia, hypotension, orthostatic symptoms
- Hemoglobin decline of more than 2 g/dL per 24 hours
- Hemoglobin below transfusion threshold (commonly 7–8 g/dL; higher for cardiovascular disease)
Management of Excessive Bleeding
- Direct pressure: sustained manual pressure for 15–20 minutes
- Topical hemostatic agents: oxidized regenerated cellulose (Surgicel), gelatin sponge (Gelfoam), or topical thrombin
- Suture closure: a single figure-of-eight suture (5-0 or 6-0 nylon) for refractory bleeding
- Transfusion: packed red blood cells as indicated by hemoglobin level and clinical context
- Discontinuation: consider terminating therapy if bleeding exceeds clinical benefit
Patient Education and Informed Consent
Informed consent for medicinal leech therapy must explicitly address the Aeromonas infection risk. Patients who understand the infectious risk and the rationale for prophylaxis are more likely to adhere to the complete antibiotic course and to report early signs of infection promptly.
Required Informed Consent Disclosures
- Infection risk: Leeches carry bacteria (Aeromonas) as natural gut symbionts; infection risk is up to about 20% without antibiotics (Graf 1999) and significantly lower with prophylaxis (Whitaker 2011)
- Antibiotic prophylaxis: Is mandatory and must be taken as prescribed for the full duration
- Bleeding risk: Each bite site oozes for 4 to 24 hours; approximately 50% of patients may require blood transfusion during treatment
- Scarring: Permanent triradiate scars (2–5 mm) at each bite site
- Treatment alternatives: Surgical revision, chemical leeching, heparin pledgets, or acceptance of tissue loss
- FDA status: Cleared as an FDA 510(k) medical device for venous congestion relief
Post-Discharge Warning Signs
Instruct patients to seek immediate medical attention if they experience any of the following within 4 weeks of treatment:
- Increasing redness, swelling, or warmth at or around the bite sites
- Pus or foul-smelling discharge from any bite wound
- Fever (temperature ≥38.0°C / 100.4°F)
- Red streaking extending from the treatment area (suggestive of lymphangitis)
- New pain disproportionate to expected healing
- Changes in the color or viability of the surgical site
Consent as Safety Requirement
Institutional Implementation
Effective Aeromonas management requires institutional infrastructure that goes beyond individual clinician prescribing. The most successful programs embed infection prevention into systems-level protocols that make adherence the default behavior.
Pre-Treatment Checklist
- Written informed consent obtained and documented, including Aeromonas infection risk disclosure
- Screening for absolute and relative contraindications completed
- Baseline labs: CBC with differential, coagulation studies (PT/INR, aPTT), basic metabolic panel
- Antibiotic prophylaxis initiated before first leech application
- Type and screen sent if multi-day therapy anticipated
- Leeches confirmed from FDA-cleared supplier; batch surveillance results reviewed
- Emergency equipment available (epinephrine, resuscitation supplies)
- Baseline clinical photographs obtained
During Treatment Checklist
- PPE worn by all personnel (gloves, gown, eye protection as indicated)
- Leeches handled with forceps, not bare hands
- Serial hematocrit or hemoglobin checks every 4 hours
- Wound site monitored for infection signs at each nursing assessment
- Flap or tissue color, turgor, and capillary refill documented at each assessment
- Antibiotic prophylaxis continued throughout treatment course
- Blood products available for transfusion if needed
Post-Treatment Checklist
- Used leeches euthanized in 70% ethanol and disposed of in biohazard waste per OSHA 29 CFR 1910.1030
- Antibiotic prophylaxis continued for minimum 24 hours (some head-and-neck protocols continue single-agent coverage for up to 2 weeks after the last application) after last application
- Patient monitored for signs of infection for up to 4 weeks
- Bite site wound care instructions provided in writing
- Follow-up appointment scheduled
Complication Reporting Protocol
- Internal: Document all infections in the medical record; notify infection control and antimicrobial stewardship teams
- Culture data: Submit susceptibility results to institutional antibiogram and batch surveillance database
- Quality improvement: Review each infection case for prophylaxis adherence, batch surveillance compliance, and potential protocol modifications
- External reporting: Consider reporting significant adverse events per institutional and regulatory requirements
Healthcare Worker Training Requirements
All personnel involved in leech therapy must receive training that covers: the biology of the medicinal leech and its bacterial symbionts; proper leech handling, application, and removal techniques; PPE donning and doffing procedures; bite wound management and dressing; recognition of Aeromonas infection signs; biohazard waste disposal procedures; post-exposure protocols; and documentation requirements. Training must be provided at the time of initial assignment and at least annually thereafter.
International Protocol Comparison
Approaches to Aeromonas prophylaxis vary between US and European practice settings, reflecting differences in regulatory frameworks, antibiotic stewardship philosophies, and clinical traditions.
| Aspect | United States | Europe |
|---|---|---|
| Regulatory framework | FDA 510(k)-cleared medical device; OSHA bloodborne pathogen requirements | CE marking; national medical device regulations vary by country |
| Standard prophylaxis | Ciprofloxacin + TMP-SMX (dual-agent); batch surveillance emerging | Variable; some centers use ciprofloxacin monotherapy; French protocol (Herlin et al.) established dual-agent standard |
| Primary context | Microsurgical salvage in academic medical centers; protocol-driven | Both surgical and traditional/naturopathic settings; broader range of indications |
| Leech supply | Ricarimpex SAS (company estimate: ~80,000/yr shipped to the U.S., 2018 report) + Biopharm UK (company estimate: just under 20,000/yr shipped to the U.S., 2018 report); both FDA-cleared | Multiple suppliers; Ricarimpex dominant; CE-marked products |
| Batch surveillance | Emerging best practice; leech-culture or tank-water surveillance protocols have been reported at individual centers (e.g., Northwestern University since 2018) | Not widely standardized; supplier-level quality controls vary |
| Annual use | ~100,000 leeches/year shipped to the U.S. (sum of two supplier estimates, ~80,000 + ~20,000; 2018 report) | Substantially higher; broader clinical use across more indications |
Evidence Summary
The evidence base for Aeromonas infection prevention in leech therapy is drawn from systematic reviews, multicenter case series, quality improvement studies, and published case reports. While no randomized controlled trials specifically compare prophylaxis regimens (such a trial would be ethically problematic given the established standard of care), the available evidence, which is mostly observational, consistently supports universal prophylaxis, while dual-agent coverage (Herlin 2017) and proactive batch surveillance (Masters 2020) rest on expert recommendation and single-center experience.
GRADE Evidence Level: Moderate
RCTs with limitations or strong observational studies
| Recommendation | Evidence Level | Key Supporting Evidence |
|---|---|---|
| Universal antibiotic prophylaxis for all leech therapy patients | Standard of care (systematic review evidence) | Whitaker 2012, de Chalain 1996, Herlin 2017, Nguyen 2012 |
| Dual-agent prophylaxis (cipro + TMP-SMX) as first-line | Recommended (systematic review + resistance data) | Herlin 2017, PMQR data 2022, 5 resistance case reports |
| Pre-application initiation of prophylaxis | Standard of care | Herlin 2017, Palm 2022, all published protocols |
| Proactive batch surveillance | Emerging best practice (quality improvement evidence) | IDCases 2020, Palm 2022 |
| EMR-integrated order panels | Strongly recommended (quality improvement evidence) | Palm 2022 |
| Avoid first-gen cephalosporins as sole prophylaxis | Contraindicated (intrinsic resistance data) | Bickel 1994 |
| Infection surveillance for 4 weeks post-treatment | Standard of care (case series evidence) | Mumcuoglu 2014, Lineaweaver 1992 |
Key Takeaways
The Numbers That Matter
- 88% of all leech therapy infections are caused by Aeromonas species
- 7–20% infection rate in most published series (de Chalain 1996); up to 20% without preemptive antibiotics (Graf 1999)
- <5% infection rate with appropriate prophylaxis
- ~78%: the flap salvage rate reported by Whitaker (277 cases, PMID 22407551)
- 6 of 21 leech-tank Aeromonas isolates not ciprofloxacin-susceptible (Wilmer 2013)
- 42% of Aeromonas isolates from a freshwater reservoir (not leech isolates) carried PMQR genes despite phenotypic fluoroquinolone susceptibility (Kosikowska 2022)
- 5 × 107 CFU/mL: bacterial density in the leech gut by 12 hours post-feeding
- At least 5 published cases of ciprofloxacin-resistant infection (Wang 2011; Patel 2013; Giltner 2013; van Alphen 2014, 2 cases)
Core Principles for Practice
- Aeromonas-active prophylaxis is the institutional standard of care — in protocol-driven hirudotherapy, refusal of antibiotic prophylaxis is treated as an absolute contraindication
- Start before the first leech — adequate tissue levels must be present before bacterial inoculation
- Dual-agent prophylaxis is the recommended standard given resistance trends
- Batch surveillance is the only strategy that addresses resistance at its source
- Never use first-gen cephalosporins (cefazolin, cephalexin) for Aeromonas coverage
- Monitor for 4 weeks post-treatment — late-onset infections are well documented
- EMR order panels eliminate reliance on individual clinician recall for prophylaxis
- Culture immediately when infection is suspected; do not wait for culture results to initiate empiric therapy
References
- Bickel KD, Lineaweaver WC, Follansbee S, et al. Intestinal flora of the medicinal leech Hirudinaria manillensis. J Reconstr Microsurg. 1994;10(2):83-85.
- de Chalain T. Exploring the use of the medicinal leech: a clinical risk-benefit analysis. J Reconstr Microsurg. 1996;12(3):165-172.
- Eroglu C, Hokelek M, Guneren E, et al. Bacterial flora of Hirudo medicinalis and their antibiotic sensitivities in the Middle Black Sea Region, Turkey. Ann Plast Surg. 2001;47(1):70-73.
- Giltner CL, Bobenchik AM, Uslan DZ, et al. Ciprofloxacin-resistant Aeromonas hydrophila cellulitis following leech therapy. J Clin Microbiol. 2013;51(4):1324-1326.
- Graf J. Symbiosis of Aeromonas veronii biovar sobria and Hirudo medicinalis, the medicinal leech: a novel model for digestive tract associations. Infect Immun. 1999;67(1):1-7.
- Herlin C, Bertheuil N, Bekara F, et al. Leech therapy in flap salvage: systematic review and practical recommendations. Ann Chir Plast Esthet. 2017;62(2):e1-e13.
- Schnabl SM, Kunz C, Unglaub F, Polykandriotis E, Horch RE, Dragu A. Acute postoperative infection with Aeromonas hydrophila after using medical leeches for treatment of venous congestion. Arch Orthop Trauma Surg. 2010;130(10):1323-1328.
- Khomyakova TI, Khomyakov YN, Borzenkova TKh. The symbiont bacterium of the medicinal leech Aeromonas hydrophila as an active agent of hirudotherapeutic action. In: Girudo-2003. Proceedings of the 8th Conference of the Association of Hirudologists of Russia and CIS Countries. Ed. Baskova IP. Moscow; 2003:47-49.
- Lineaweaver WC, Hill MK, Buncke GM, et al. Aeromonas hydrophila infections following use of medicinal leeches in replantation and flap surgery. Ann Plast Surg. 1992;29(3):238-244.
- Merino S, Rubires X, Aguilar A, et al. Mesophilic Aeromonas sp. serogroup O:11 resistance to complement-mediated killing. Infect Immun. 1996;64(12):5302-5309.
- Mumcuoglu KY. Recommendations for the use of leeches in reconstructive plastic surgery. Evid Based Complement Alternat Med. 2014;2014:205929.
- Multidrug resistant Aeromonas infection following medical leech therapy: a case report and development of a joint antimicrobial stewardship and infection prevention protocol. J Glob Antimicrob Resist. 2020;23:349-351.
- Nguyen MQ, Crosby MA, Skoracki RJ, Hanasono MM. Outcomes of flap salvage with medicinal leech therapy. Microsurgery. 2012;32(5):351-357.
- Nonomura H, Kato N, Ohno Y, et al. Indigenous bacterial flora of medicinal leeches and their susceptibilities to 15 antimicrobial agents. J Med Microbiol. 1996;45(6):490-493.
- Palm NM, Wesolowski JC, Wu JY, Srinivas P. Implementation of a leeches + antimicrobial prophylaxis order panel to optimize medicinal leech use at a tertiary care academic medical center. J Pharm Pract. 2022;35(3):427-430.
- Patel KM, Svestka M, Sinkin J, Ruff P 4th. Ciprofloxacin-resistant Aeromonas hydrophila infection following leech therapy. J Plast Reconstr Aesthet Surg. 2013;66(1):e20-22.
- Rajaram R, Cevik J, Bhindi N, Seth I, Rozen WM. The use of medicinal leeching in breast surgery: a systematic review. J Clin Med. 2024;13(5):1243.
- Whitaker IS, Oboumarzouk O, Rozen WM, et al. The efficacy of medicinal leeches in plastic and reconstructive surgery: a systematic review of 277 reported clinical cases. Microsurgery. 2012;32(3):240-250.
- van Alphen NA, Gonzalez A, McKenna MC, McKenna TK, Carlsen BT, Moran SL. Ciprofloxacin-resistant Aeromonas infection following leech therapy for digit replantation: report of 2 cases. J Hand Surg Am. 2014;39(3):499-502.
- Ciprofloxacin-resistant A. hydrophila complicating leech therapy in free flap surgery. JPRAS Open. 2025.
- Kosikowska U, Stec J, Andrzejczuk S, et al. Plasmid-mediated fluoroquinolone resistance genes in quinolone-susceptible Aeromonas spp. phenotypes isolated from recreational surface freshwater reservoir. Front Cell Infect Microbiol. 2022;12:885360.
- Lethal Aeromonas veronii sepsis in the course of medicinal leech therapy. Antibiotics. 2022;11(9):1180.
- Aeromonas meningitis complicating medicinal leech therapy. Clin Infect Dis. 2004;38(4):e36-37.
- OSHA. Bloodborne Pathogens Standard. 29 CFR 1910.1030. U.S. Department of Labor.
- FDA. Product classification: leeches, medicinal (NRN). 510(k) K040187 (Ricarimpex SAS, 2004).